Drug Profile
Research programme: TREM-1 targeted therapeutics - Novo Nordisk
Alternative Names: hTREM1-IgG fusion protein - Novo Nordisk; TREM-1 - Novo NordiskLatest Information Update: 05 Sep 2014
Price :
$50
*
At a glance
- Originator BioXell SpA
- Developer Novo Nordisk
- Class Proteins
- Mechanism of Action TREM modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Inflammatory bowel diseases; Septic shock